Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(25 sites)
France
Institut de Cancérologie de l'Ouest, Angers Institut Bergonié, Bordeaux Centre Francois Baclesse, Caen CHU Henri Mondor, Créteil Last updated December 2024